English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Janssen
+
Regulatory
Press release submission
| Dec 29, 2021
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
+
Regulatory
Press release submission
| Dec 22, 2021
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
+
Regulatory
Press release submission
| Aug 19, 2021
Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
+
Regulatory
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
+
Regulatory
Press release submission
| Jan 16, 2019
JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
+
Regulatory
Press release submission
| Dec 6, 2018
JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Trending
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Regulatory
M. R. Armstrong
| Aug 4, 2026
Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+
Pharmaceuticals
Patient Daily
| Aug 5, 2026
Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes
